Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19
Revive Therapeutics Ltd. (RVV) has provided an update on the company’s U.S. Food & Drug Administration (FDA) Phase 3 clinical trial.
The trial is to evaluate the safety and efficacy of Bucillamine – an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
The Market Herald Canada’s Dave Jackson reports.
Click here to read the full story
Weekly Update – Top Cannabis and Psychedelics News Stories
1 | Top Story: HAVN Life Sciences Inc. (CSE:HAVN) to supply psilocybin products for medical psilocybin & data project.
2 | MediPharm Labs Corp. (TSX:LABS) awarded favourable judgement in the Ontario Court of Justice.
3 | Algernon Pharmaceuticals Inc. (CSE:AGN) reports “additional positive data” from Phase 2 Study of Ifenprodil.
4 | Curaleaf Holdings Inc. (CSE:CURA) launches new product line targeting specific health & wellness categories.
5 | Nextleaf Solutions Ltd. (CSE:OILS) develops technology to produce distilled THC-free CBD oil.
Top Cannabis Stocks July 21 to July 27, 2022
1. T.HEXO | 13,734 views | Hexo Corp.
2. T.WEED |12,744 views | Canopy Growth Corp. Stock.
3. TLRY | 7,778 views | Tilray Brands Inc.
4. C.OILS | 3,824 views | Nextleaf Solutions Ltd.
5. C.TNY | 3,603 views | Tinley Beverage Co Inc.
6. T.TBP | 2,269 views | Tetra Bio-Pharma Inc.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.